Celularity Inc. Business Acquisition, Transaction Costs
Celularity Inc. (CELU) had Business Acquisition, Transaction Costs of $21.66 million as of 2021-07-16, per its 10-K filed 2023-03-31.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Description
us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts · last filed 2023-03-31
- 2021-07-16: Business Acquisition, Transaction Costs $21.66M.
| Period end | Business Acquisition, Transaction Costs |
|---|---|
| 2021-07-16 | $21.66M 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |